Cereno Scientific Advances CS1 Clinical Trials for PAH Treatment
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech focusing on treatments to enhance life for individuals suffering from rare cardiovascular and pulmonary conditions, has made a significant step forward. The company has submitted the clinical trial protocol for its leading drug candidate, CS1, to the U.S. Food and Drug Administration (FDA). This submission represents a pivotal moment in the journey towards a groundbreaking therapeutic solution for pulmonary arterial hypertension (PAH).
The upcoming Phase IIb trial aims to evaluate CS1’s safety, tolerability, and efficacy more comprehensively. CS1 is a histone deacetylase inhibitor (HDACi) developed as an oral treatment targeting the underlying mechanisms of PAH through innovative epigenetic modulation. This trial follows a successful Phase IIa trial, where CS1 exhibited a commendable safety profile and showed promising efficacy signals, including reverse vascular remodeling and improved heart function, alongside enhancing patient quality of life.
Understanding the Phase IIb Trial
The Phase IIb trial is designed to refine the findings from the previous studies and will be conducted globally with the support of a reputable international contract research organization (CRO). This collaborative effort aims to establish CS1 as a viable treatment option for patients battling PAH. Regulatory discussions in other strategic markets are also on the horizon as part of the global launch preparations.
Rahul Agrawal, CMO and Head of R&D, emphasized the achievement by stating, "The submission of the protocol underscores our team's dedication and collaboration with our global CRO. It has been crafted with regard to the FDA's feedback from our Type C meeting, and we await their review with anticipation as we prepare to kick-start the trial."
The Challenge of Pulmonary Arterial Hypertension
PAH is characterized by abnormally high blood pressure within the pulmonary arteries, which can lead to severe complications, including heart failure and an increased risk of premature death. Current treatments primarily manage symptoms rather than addressing the disease's root causes, highlighting a significant need for effective disease-modifying therapies that can alter the condition's trajectory. Cereno Scientific’s approach with CS1 aims to fill this gap.
Sten R. Sörensen, the CEO of Cereno Scientific, stated, "This milestone brings us closer to delivering a first-in-class therapy that directly targets the underlying mechanisms of PAH. Our work with CS1 represents a chance to revolutionize treatment for patients experiencing this debilitating condition, ultimately providing substantial long-term benefits for both patients and shareholders."
Looking Ahead with CS1
Cereno Scientific anticipates that after the FDA’s review, which typically lasts around 30 days, they will receive clearance to initiate the Phase IIb trial. This trial is expected to commence in the first half of 2026 as part of the broader global development strategy for CS1.
CS1 stands out as an orally administered histone deacetylase inhibitor that offers an innovative, disease-modifying treatment approach for pulmonary arterial hypertension. Through its epigenetic modulation capabilities, CS1 targets critical mechanisms driving PAH, including inflammation and vascular remodeling. This promising drug has already demonstrated significant potential in early clinical assessments, paving the way for future studies.
About Cereno Scientific
Cereno Scientific is committed to creating treatments that improve and extend life, with a robust pipeline of innovative drug candidates aimed at empowering patients suffering from rare pulmonary and cardiovascular diseases. CS1, the company’s lead candidate, works by utilizing epigenetic modulation to address the core aspects of pulmonary arterial hypertension.
In addition to CS1, the company is exploring the potential of CS014, a new chemical entity indicating promising disease-modifying properties observed during its Phase I trial. With the preclinical compound CS585, which acts as a potent prostacyclin receptor agonist, the company aims to tackle severe cardiovascular conditions.
Cereno Scientific is headquartered in the vibrant GoCo Health Innovation City in Gothenburg, Sweden, with a U.S. subsidiary located in Boston, Massachusetts. The firm remains committed to its vision of developing breakthrough therapies that make a difference in the lives of individuals facing critical health challenges.
Frequently Asked Questions
What is CS1?
CS1 is Cereno Scientific's leading drug candidate that is currently in development as an oral treatment for pulmonary arterial hypertension.
What is the purpose of the Phase IIb trial?
The Phase IIb trial aims to evaluate the safety, tolerability, and effectiveness of CS1 following promising results from previous trials.
How does CS1 work?
CS1 functions as a histone deacetylase inhibitor, targeting underlying processes of PAH through epigenetic modulation to potentially reverse disease progression.
What did previous trials reveal about CS1?
The earlier Phase IIa trial highlighted CS1's favorable safety profile and encouraging efficacy signals, including significant improvements in vascular remodeling and heart function.
When will the Phase IIb trial begin?
The Phase IIb trial is scheduled to begin in the first half of 2026, pending FDA approval following the 30-day review period.
